Work

Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer

Year: 2010

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs10-s4-3

Authors: M Martin, J Mackey, T Pienkowski, J Rolski, J-P Guastalla, A Sami, J Glaspy, E Juhos, A Wardley, T Fornander, J Hainsworth, R Coleman, M Modiano, J Vinholes, T Pinter, B Childs, M Roessner, V Wilson, M Rupin, C Vogel

Institutions: Sarah Cannon, Centre Léon Bérard, National Institute of Oncology, The Christie Hospital, Cross Cancer Institute

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2078090476

Cites:

Cited by: 3

Related to: 10